EA201790373A1 - Способы получения модуляторов toll-подобных рецепторов - Google Patents
Способы получения модуляторов toll-подобных рецепторовInfo
- Publication number
- EA201790373A1 EA201790373A1 EA201790373A EA201790373A EA201790373A1 EA 201790373 A1 EA201790373 A1 EA 201790373A1 EA 201790373 A EA201790373 A EA 201790373A EA 201790373 A EA201790373 A EA 201790373A EA 201790373 A1 EA201790373 A1 EA 201790373A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- toll
- modulators
- obtaining
- methods
- similar receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/60—Three or more oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
Abstract
В настоящем изобретении предложены способы получения 4-амино-2-бутокси-8-(3-(пирролидин-1-илметил)бензил)-7,8-дигидроптеридин-6(5Н)-она и родственных соединений.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462051044P | 2014-09-16 | 2014-09-16 | |
PCT/US2015/050039 WO2016044183A1 (en) | 2014-09-16 | 2015-09-14 | Methods of preparing toll-like receptor modulators |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201790373A1 true EA201790373A1 (ru) | 2017-08-31 |
Family
ID=54291584
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201790373A EA201790373A1 (ru) | 2014-09-16 | 2015-09-14 | Способы получения модуляторов toll-подобных рецепторов |
Country Status (20)
Country | Link |
---|---|
US (1) | US9573952B2 (ru) |
EP (3) | EP3848375B1 (ru) |
JP (4) | JP6373490B2 (ru) |
KR (3) | KR102457426B1 (ru) |
CN (2) | CN107074860B (ru) |
AR (1) | AR101882A1 (ru) |
AU (2) | AU2015318062B2 (ru) |
BR (1) | BR112017005100A2 (ru) |
CA (1) | CA2960384C (ru) |
EA (1) | EA201790373A1 (ru) |
ES (2) | ES2845205T3 (ru) |
IL (1) | IL250849A0 (ru) |
MX (1) | MX2017003288A (ru) |
NZ (1) | NZ729526A (ru) |
PL (1) | PL3461828T3 (ru) |
PT (2) | PT3461828T (ru) |
SG (1) | SG11201701472VA (ru) |
SI (1) | SI3461828T1 (ru) |
TW (2) | TWI780423B (ru) |
WO (1) | WO2016044183A1 (ru) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2364314B1 (en) | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
NZ728072A (en) | 2014-07-11 | 2018-06-29 | Gilead Sciences Inc | Modulators of toll-like receptors for the treatment of hiv |
JP2017526730A (ja) | 2014-09-16 | 2017-09-14 | ギリアード サイエンシーズ, インコーポレイテッド | Toll様受容体モジュレーターの固体形態 |
CN111065636B (zh) * | 2017-09-22 | 2022-08-23 | 江苏恒瑞医药股份有限公司 | 稠合杂芳基衍生物、其制备方法及其在医药上的应用 |
WO2023212121A2 (en) * | 2022-04-26 | 2023-11-02 | Bigelow Laboratory For Ocean Sciences | Methods for producing halogenated compounds |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
JP2886570B2 (ja) | 1989-09-29 | 1999-04-26 | エーザイ株式会社 | 縮合ヘテロ環を有する化合物 |
JPH05320143A (ja) * | 1992-03-18 | 1993-12-03 | Mochida Pharmaceut Co Ltd | 新規ピリミジン誘導体 |
TW274550B (ru) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
US5620978A (en) | 1994-01-03 | 1997-04-15 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon, Eugene Oregon | 8-aza, 6-aza and 6,8-diaza-1,4-dihydroquinoxaline-2,3-diones and the use thereof as antagonists for the glycine/NMDA receptor |
ZA973884B (en) | 1996-05-23 | 1998-11-06 | Du Pont Merck Pharma | Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders |
KR20000029843A (ko) | 1996-08-06 | 2000-05-25 | 디. 제이. 우드;스피겔 알렌 제이 | 치환된피리도-또는피리미도-함유6,6-또는6,7-비시클릭유도체 |
US5693641A (en) | 1996-08-16 | 1997-12-02 | Berlex Laboratories Inc. | Bicyclic pyrimidine derivatives and their use as anti-coagulants |
EP1089979A1 (en) | 1998-06-26 | 2001-04-11 | Du Pont Pharmaceuticals Company | Substituted quinoxalin-2(1h)-ones useful as hiv reverse transcriptase inhibitors |
EP1409487A1 (en) | 1999-09-15 | 2004-04-21 | Warner-Lambert Company Llc | Pteridinones as kinase inhibitors |
US6452325B1 (en) | 2000-07-24 | 2002-09-17 | Thermoplastic Processes, Inc. | Shatterproofing of fluorescent lamps |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
WO2003020722A1 (de) | 2001-09-04 | 2003-03-13 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CN101200457A (zh) | 2003-02-26 | 2008-06-18 | 贝林格尔英格海姆法玛两合公司 | 二氢蝶啶酮、其制法及作为药物制剂的用途 |
CA2565500A1 (en) | 2004-05-28 | 2005-12-15 | Glaxosmithkline Biologicals S.A. | Vaccine compositions comprising virosomes and a saponin adjuvant |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
EP1888587A1 (en) | 2005-05-04 | 2008-02-20 | Pfizer Limited | 2-amido-6-amino-8-oxopurine derivatives as toll-like receptor modulators for the treatment of cancer and viral infections, such as hepatitis c |
EP1915155A1 (en) | 2005-08-03 | 2008-04-30 | Boehringer Ingelheim International GmbH | Dihydropteridinones in the treatment of respiratory diseases |
JPWO2007034917A1 (ja) | 2005-09-22 | 2009-03-26 | 大日本住友製薬株式会社 | 新規なアデニン化合物 |
PL1942108T3 (pl) * | 2005-10-28 | 2014-03-31 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową i jego zastosowanie |
CA2644850A1 (en) * | 2006-03-08 | 2007-09-13 | Amgen Inc. | Quinoline and isoquinoline derivatives as phosphodiesterase 10 inhibitors |
EP2004193A2 (en) | 2006-03-13 | 2008-12-24 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
CN101479269A (zh) | 2006-06-23 | 2009-07-08 | 阿斯利康(瑞典)有限公司 | 蝶啶衍生物及其作为组织蛋白酶抑制剂的用途 |
ZA200902382B (en) | 2006-10-19 | 2010-08-25 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors |
WO2008101867A1 (en) | 2007-02-19 | 2008-08-28 | Smithkline Beecham Corporation | Purine derivatives as immunomodulators |
EP2139892B1 (en) | 2007-03-22 | 2011-09-14 | Takeda Pharmaceutical Company Limited | Substituted pyrimidodiazepines useful as plk1 inhibitors |
WO2008124575A1 (en) * | 2007-04-05 | 2008-10-16 | Smithkline Beecham Corporation | Renin inhibitors |
US7829063B2 (en) * | 2007-04-05 | 2010-11-09 | Siemens Medical Solutions Usa, Inc. | Development of molecular imaging probes for carbonic anhydrase-IX using click chemistry |
CA2680769C (en) * | 2007-04-18 | 2015-10-13 | Kissei Pharmaceutical Co., Ltd. | Nitrogenated fused ring derivative, pharmaceutical composition comprising the same, and use of the same for medical purposes |
CA2695753A1 (en) | 2007-08-15 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Compounds useful as protein kinases inhibitors |
WO2009022185A2 (en) | 2007-08-16 | 2009-02-19 | Astrazeneca Ab | 6, 6-fused heterocycles, their pharmaceutical compositions and methos of use |
US20090291938A1 (en) | 2007-11-19 | 2009-11-26 | Takeda Pharmaceutical Company Limited | Polo-like kinase inhibitors |
CN101284810A (zh) * | 2008-06-02 | 2008-10-15 | 秦引林 | 氰基吡咯烷和氰基噻唑烷衍生物 |
EP2364314B1 (en) * | 2008-12-09 | 2014-03-12 | Gilead Sciences, Inc. | Modulators of toll-like receptors |
NO2477987T3 (ru) * | 2009-09-14 | 2018-06-09 | ||
CA2822037A1 (en) * | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
-
2015
- 2015-09-14 CN CN201580050126.2A patent/CN107074860B/zh active Active
- 2015-09-14 SG SG11201701472VA patent/SG11201701472VA/en unknown
- 2015-09-14 CN CN202210865358.5A patent/CN115043840A/zh active Pending
- 2015-09-14 CA CA2960384A patent/CA2960384C/en active Active
- 2015-09-14 EP EP20207453.0A patent/EP3848375B1/en active Active
- 2015-09-14 NZ NZ729526A patent/NZ729526A/en not_active IP Right Cessation
- 2015-09-14 WO PCT/US2015/050039 patent/WO2016044183A1/en active Application Filing
- 2015-09-14 AU AU2015318062A patent/AU2015318062B2/en active Active
- 2015-09-14 JP JP2017514494A patent/JP6373490B2/ja active Active
- 2015-09-14 KR KR1020217030537A patent/KR102457426B1/ko active IP Right Grant
- 2015-09-14 EA EA201790373A patent/EA201790373A1/ru unknown
- 2015-09-14 SI SI201531451T patent/SI3461828T1/sl unknown
- 2015-09-14 KR KR1020197013364A patent/KR102306860B1/ko active Application Filing
- 2015-09-14 EP EP15778411.7A patent/EP3194402B1/en active Active
- 2015-09-14 KR KR1020177009930A patent/KR101978809B1/ko active IP Right Grant
- 2015-09-14 EP EP18205728.1A patent/EP3461828B1/en active Active
- 2015-09-14 PL PL18205728T patent/PL3461828T3/pl unknown
- 2015-09-14 US US14/853,883 patent/US9573952B2/en active Active
- 2015-09-14 BR BR112017005100A patent/BR112017005100A2/pt active Search and Examination
- 2015-09-14 TW TW109111477A patent/TWI780423B/zh active
- 2015-09-14 ES ES18205728T patent/ES2845205T3/es active Active
- 2015-09-14 TW TW104130275A patent/TWI692468B/zh active
- 2015-09-14 MX MX2017003288A patent/MX2017003288A/es unknown
- 2015-09-14 ES ES15778411T patent/ES2706527T3/es active Active
- 2015-09-14 PT PT182057281T patent/PT3461828T/pt unknown
- 2015-09-14 PT PT15778411T patent/PT3194402T/pt unknown
- 2015-09-16 AR ARP150102954A patent/AR101882A1/es unknown
-
2017
- 2017-02-28 IL IL250849A patent/IL250849A0/en unknown
-
2018
- 2018-07-17 JP JP2018134200A patent/JP6596127B2/ja active Active
- 2018-09-27 AU AU2018236824A patent/AU2018236824B2/en active Active
-
2019
- 2019-09-27 JP JP2019176572A patent/JP7063865B2/ja active Active
-
2022
- 2022-02-04 JP JP2022016438A patent/JP7333843B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201790369A1 (ru) | Твердые формы модулятора толл-подобного рецептора | |
CY1125032T1 (el) | Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου | |
EA201790984A1 (ru) | Анти-cd79b антитела и способы их применения | |
EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
MY192927A (en) | Fused bicyclic compounds for the treatment of disease | |
EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
EA201691991A1 (ru) | Мультиспецифические антитела | |
EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
CL2016003416A1 (es) | Herbicidas de piperidinona | |
ES2796903T8 (es) | Procedimiento de uso de inmunoconjugados anti-CD79b | |
CL2016002731A1 (es) | Herbicidas de piridazinona | |
MX2017008456A (es) | Compuestos biciclicos fusionados para el tratamiento de enfermedades. | |
EA201791117A1 (ru) | Частичные агонисты инсулинового рецептора | |
EA201691610A1 (ru) | Анти-jagged1 антитела и способы применения | |
EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
MA46963A (fr) | Méthodes pour déterminer le dosage de céllules car-t | |
EA201790967A1 (ru) | Химерные антигенные рецепторы против cldn и способы их применения | |
EA201791421A1 (ru) | Антитела против csf1r для лечения pvns | |
CL2019001381A1 (es) | Método para el tratamiento de glomeruloesclerosis segmentaria focal. | |
EA201790373A1 (ru) | Способы получения модуляторов toll-подобных рецепторов | |
DK3265459T3 (da) | Amidforbindelser som 5-ht4-receptoragonister | |
CO2017010621A2 (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades | |
MX2018005987A (es) | Compuestos heterociclicos para el tratamiento de enfermedades. | |
MX2017011454A (es) | Procesos para preparar fluorocetólidos. | |
MX2018014034A (es) | Compuestos bicíclicos fusionados para el tratamiento de enfermedades. |